Results 241 to 250 of about 52,371 (280)
Some of the next articles are maybe not open access.
Management of relapsed/refractory DLBCL
Best Practice & Research Clinical Haematology, 2018Diffuse large B cell lymphoma represents the most common type of non-Hodgkin lymphoma. Although the curability rate is high, around 40% of patients will relapse or exhibit refractory disease. To obtain long-term disease-free survival after relapse, an intensive salvage regimen followed by autologous steam cell transplant remains the standard of care ...
Clémentine, Sarkozy, Laurie H, Sehn
openaire +2 more sources
Optimizing initial therapy in DLBCL
Best Practice & Research Clinical Haematology, 2018Diffuse large B-cell lymphoma (DLBCL) is a group of lymphomas comprising heterogeneous molecular and biological subtypes, reflected in a broad range of clinical outcomes. With the standard R-CHOP regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab administered every 21 days, the treatment failure rate remains ...
Catherine, Thieblemont +3 more
openaire +2 more sources
Blood, 2013
![Figure][1] A 70-year-old woman presented with 4 weeks of progressive bilateral lower extremity weakness. She had past medical history of stage III diffuse large B-cell lymphoma treated with 6 cycles of R -CHOP chemotherapy, which was completed 6 months prior to presentation.
openaire +2 more sources
![Figure][1] A 70-year-old woman presented with 4 weeks of progressive bilateral lower extremity weakness. She had past medical history of stage III diffuse large B-cell lymphoma treated with 6 cycles of R -CHOP chemotherapy, which was completed 6 months prior to presentation.
openaire +2 more sources
Novel molecular classifications of DLBCL
Nature Reviews Clinical Oncology, 2018Recent genomic and transcriptomic analyses of diffuse large B cell lymphoma (DLBCL) have provided important new insights into the heterogeneous biology of this disease. The findings provide opportunities to improve treatment strategies, although considerable work is needed to establish and optimize the clinical applicability and utility of molecular ...
Dubois, Sydney, Jardin, Fabrice
openaire +3 more sources
Ibrutinib promising in subtype of DLBCL
The Lancet Oncology, 2015Patients with the activated B-celllike (ABC) subtype of diff use large B-cell lymphoma were more likely to respond to ibrutinib than were those with the germinal centre B-celllike (GCB) subtype of the disease, according to results of a phase 2 study.
openaire +2 more sources
Blood, 2008
In this issue of Blood , Lam and colleagues report synergistic crosstalk between NF-κB and the JAK/STAT pathway in a subset of diffuse large B-cell lymphoma (DLBCL) that might have implications for future targeted therapies.
openaire +1 more source
In this issue of Blood , Lam and colleagues report synergistic crosstalk between NF-κB and the JAK/STAT pathway in a subset of diffuse large B-cell lymphoma (DLBCL) that might have implications for future targeted therapies.
openaire +1 more source
Curative intent therapy for DLBCL in the elderly
Leukemia & LymphomaOlder patients with aggressive lymphoma are extremely heterogeneous due to the high frequency of functional limitations and comorbidities and to the different biological profiles and clinical behavior of the disease. The stratification in three geriatric categories (fit-unfit-frail) based on multidimensional geriatric assessment (GA) helps physicians ...
Alessandra, Tucci +2 more
openaire +2 more sources
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
Cancer Cell, 2021Louis M Staudt +2 more
exaly